Samsung Biologics secondary share sale draws $8 billion

Samsung Biologics Plant 4 in Songdo Courtesy of Samsung Biologics
Samsung Biologics' Plant 4 in Songdo/ Courtesy of Samsung Biologics
 
SEOUL, November 16 (AJP) - Investors poured more than 11 trillion won ($8.23 billion) into the public tranche of Samsung Biologics' rights offering, which will fund South Korea's biggest-ever drug industry takeover, the company said Monday.

Orders for about 9.75 million shares chased just 71,854 shares in the two-day offering that ended Friday, a subscription ratio of 135.6 to 1. An investor had to put up about 160 million won in deposits to secure a single share at the final price of 1,174,000 won.

Deposits totaled 11.44 trillion won, the most ever for a Korean rights issue that went on to a public offering, the company said.

As of 11:00 a.m. Monday, shares were 0.57 percent lower at 1,404,000 won. 

Existing shareholders and employees had already taken up 96.8 percent of the 2.27 million new shares, with major shareholders Samsung C&T and Samsung Electronics subscribing in full.

The sale will raise 2.67 trillion won, short of the 3 trillion won targeted in August, because the final price came in below the indicative 1,322,000 won.

All of the money goes toward PolyPeptide Group, the Swiss peptide producer Samsung Biologics agreed in July to buy for 1.46 billion Swiss francs ($1.8 billion).

The deal takes the contract drug manufacturer beyond antibodies, messenger RNA and antibody-drug conjugates into peptides, the building blocks of popular obesity and diabetes drugs.

"We launched this rights offering to lay the groundwork for our leap to become a global top-tier CDMO," Chief Executive John Rim said in August.

PolyPeptide runs six production sites in the United States, Europe and India. Holders of 97.98 percent of its shares accepted a recent tender offer, and Samsung Biologics plans to squeeze out the rest.

Payment for the new shares is due Tuesday, and the shares are set to list Nov. 30.